GCC Liquid Biopsy Market Overview
The GCC liquid biopsy market is witnessing significant growth as healthcare systems across Saudi Arabia, the United Arab Emirates (UAE), Qatar, Kuwait, Bahrain, and Oman increasingly adopt advanced molecular diagnostic technologies. Liquid biopsy offers a minimally invasive method for analyzing tumor-related genetic material and other biomarkers in blood, supporting cancer diagnosis, treatment selection, therapy monitoring, and disease recurrence assessment.
According to Renub Research, the GCC liquid biopsy market is projected to increase from US$ 11.61 million in 2025 to US$ 36.58 million by 2034, registering a compound annual growth rate (CAGR) of 13.6% during 2026–2034.
The market’s expansion is supported by rising cancer incidence, increasing investments in precision medicine, greater availability of next-generation sequencing (NGS), and the modernization of healthcare infrastructure. Hospitals and diagnostic laboratories are increasingly exploring molecular testing solutions that can provide clinically relevant information without requiring repeated invasive tissue biopsies.
Saudi Arabia and the UAE are important markets because of their investments in advanced oncology services, genomic medicine, and molecular diagnostic infrastructure. Meanwhile, regional collaborations involving healthcare institutions and international diagnostic technology providers are helping expand access to blood-based genomic profiling.
Although high testing costs, reimbursement limitations, technical complexity, and shortages of specialized professionals remain challenges, continued investment in precision oncology is expected to create opportunities for diagnostic companies, laboratory service providers, and manufacturers of liquid biopsy kits and instruments.
What Is Liquid Biopsy and Why Is It Important in the GCC?
Liquid biopsy is a minimally invasive diagnostic technique that analyzes biological material released by tumors into body fluids, particularly blood. Depending on the test, it can identify circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), circulating tumor cells (CTCs), and other molecular biomarkers.
Unlike conventional tissue biopsy, which requires collecting a sample from a tumor, liquid biopsy can provide molecular information through a blood draw. Its clinical applications include identifying actionable mutations, guiding targeted treatment decisions, monitoring treatment response, detecting emerging drug resistance, and assessing minimal residual disease or potential cancer recurrence.
Liquid biopsy is becoming increasingly relevant to GCC healthcare systems as countries invest in advanced cancer care and personalized medicine. The technology can help clinicians obtain molecular information during different stages of a patient’s treatment journey.
According to the source material, the GCC recorded approximately 42,475 new cancer cases and 19,895 cancer deaths in 2020. Breast, colorectal, and thyroid cancers accounted for nearly 40% of new cases. The number of new cancer cases could approach 103,000 by 2040 if current incidence rates remain unchanged.
These figures highlight the importance of strengthening cancer diagnosis and monitoring capabilities. However, liquid biopsy should not be considered a universal replacement for tissue biopsy or a definitive screening test for every cancer. Its suitability depends on the cancer type, clinical indication, test performance, and applicable medical guidelines.
Key Growth Drivers of the GCC Liquid Biopsy Market
1. Rising Cancer Burden and Demand for Early Detection
The increasing burden of cancer is a major factor supporting liquid biopsy adoption across the GCC. Healthcare providers need diagnostic technologies that can help characterize tumors, guide treatment, and monitor disease progression.
Liquid biopsy offers several practical advantages, including minimally invasive sample collection and the ability to perform repeat molecular assessments. These characteristics make it useful in selected clinical situations where tumor tissue is difficult to obtain or where molecular changes need to be monitored over time.
Growing awareness of cancer prevention and early diagnosis is also encouraging healthcare institutions to strengthen their diagnostic capabilities. As oncology services increasingly incorporate molecular information into clinical decisions, demand for ctDNA analysis, cfDNA testing, and NGS-based genomic profiling is expected to expand.
2. Expansion of Precision Oncology and Genomic Testing
Precision oncology is another important growth driver. Rather than relying exclusively on the location or appearance of a tumor, precision medicine uses molecular information to help determine which treatments may be appropriate for individual patients.
Liquid biopsy can identify specific genetic alterations associated with certain cancers and help clinicians evaluate potential targeted treatment options. It can also support the identification of emerging resistance mutations in selected clinical settings.
Saudi Arabia has demonstrated progress in this area. King Faisal Specialist Hospital & Research Centre adopted liquid biopsy technology capable of analyzing approximately 50 cancer-related genes and more than 3,000 clinically relevant mutations from a 10 mL blood sample, according to the source material.
Such developments illustrate the growing role of molecular diagnostics in regional cancer care. Continued investment in genomic sequencing, bioinformatics, laboratory infrastructure, and clinical interpretation is expected to support market expansion.
3. Healthcare Modernization and Investment in Advanced Diagnostics
GCC countries are strengthening healthcare infrastructure through investments in specialized hospitals, oncology centers, molecular laboratories, and precision-health programs.
These initiatives create opportunities for liquid biopsy providers across several parts of the value chain, including diagnostic kits, reagents, sequencing instruments, laboratory services, and genomic interpretation platforms.
The technology is particularly relevant to healthcare institutions seeking to integrate molecular testing into routine oncology workflows. However, successful adoption requires more than purchasing equipment. Hospitals also need validated testing procedures, trained personnel, quality-control systems, and clear clinical pathways for interpreting results.
As these capabilities develop, liquid biopsy is expected to become an increasingly relevant component of advanced cancer diagnostics across the region.
Challenges Facing the GCC Liquid Biopsy Market
High Testing Costs and Limited Reimbursement
The cost of liquid biopsy remains a barrier to broader adoption. Advanced tests may require specialized sample processing, sensitive molecular detection technologies, NGS platforms, bioinformatics systems, and experienced laboratory professionals.
These requirements can increase the overall cost of testing, particularly for comprehensive genomic panels and emerging applications such as minimal residual disease monitoring.
Inconsistent reimbursement arrangements may also limit adoption when patients or healthcare providers must pay significant out-of-pocket expenses. Expanding appropriate insurance coverage, demonstrating clinical utility and cost-effectiveness, and increasing local testing capacity could help address these barriers.
Technical Complexity and Skilled-Labor Requirements
Liquid biopsy requires highly sensitive analytical methods because tumor-derived genetic material can be present at very low concentrations in blood. Sample handling, sequencing errors, biological variability, and differences in laboratory protocols can affect results.
The interpretation of complex genomic data also requires specialized expertise in molecular diagnostics, pathology, genetics, and bioinformatics.
Although GCC countries are developing their precision-medicine capabilities, specialized expertise may remain concentrated in major healthcare centers. Investment in professional training, laboratory accreditation, standardized procedures, and quality assurance will be important for maintaining reliable testing standards.
GCC Liquid Biopsy Market Trends and Emerging Opportunities
Circulating Tumor DNA Testing
Circulating tumor DNA is an important component of the liquid biopsy market. It can provide information about tumor-associated genetic alterations and support treatment selection, therapy monitoring, and the assessment of molecular recurrence risk in appropriate clinical settings.
Advances in NGS and other molecular technologies are improving the capabilities of ctDNA testing. Saudi Arabia and the UAE are particularly important markets because of their developing precision-oncology infrastructure and investments in advanced genomic diagnostics.
Growth in Kits, Reagents, and Laboratory Services
The expansion of molecular testing creates recurring demand for DNA extraction kits, ctDNA isolation reagents, CTC enrichment products, mutation-detection assays, and NGS library-preparation materials.
The market also includes platforms and instruments and testing services. As laboratories increase testing volumes, suppliers may benefit from demand for consumables, specialized equipment, sample processing, and genomic interpretation.
Local laboratory capacity and the availability of reliable supplies will influence the pace of adoption across GCC countries.
Expansion Beyond Oncology
Although cancer diagnosis and treatment remain central applications, liquid biopsy technologies also have relevance in reproductive health. Cell-free DNA testing is used in non-invasive prenatal testing (NIPT) to screen for certain fetal chromosomal abnormalities using a maternal blood sample.
This application is distinct from oncology-focused liquid biopsy, but it demonstrates the broader role of blood-based molecular analysis in healthcare.
Greater access to genomic medicine, prenatal screening, and genetic counseling may create additional opportunities for molecular diagnostic providers across the GCC.
Country-Level Analysis of the GCC Liquid Biopsy Market
Saudi Arabia
Saudi Arabia is a leading market for liquid biopsy adoption in the GCC. Its advanced oncology infrastructure, investments in genomic medicine, and growing emphasis on personalized treatment create opportunities for ctDNA testing, cfDNA analysis, NGS-based profiling, and molecular monitoring.
The adoption of advanced liquid biopsy technology at King Faisal Specialist Hospital & Research Centre illustrates the country’s progress in integrating genomic diagnostics into clinical care.
United Arab Emirates
The UAE is strengthening its precision-oncology ecosystem through investments in molecular laboratories and partnerships with international healthcare and technology organizations.
In June 2025, M42, AstraZeneca, and SOPHiA GENETICS announced a collaboration to introduce MSK-ACCESS liquid biopsy testing into UAE healthcare infrastructure. The initiative initially targeted genomic profiling for lung, ovarian, breast, colorectal, and pancreatic cancers, with validation studies planned at Cleveland Clinic Abu Dhabi.
These developments are expected to support the expansion of advanced molecular diagnostics in the country.
Bahrain
Bahrain’s liquid biopsy market is developing alongside demand for improved cancer diagnosis and monitoring. The 2024 Bahrain National Cancer Registry recorded 1,401 new cancer cases, according to the source material.
Liquid biopsy could complement conventional diagnostic methods by helping clinicians assess tumor-related biomarkers and monitor molecular changes during treatment. Regional genomics initiatives may also support the development of testing capabilities.
Kuwait
Kuwait is benefiting from broader GCC investment in genomic medicine and personalized cancer care. Liquid biopsy can support molecular profiling, treatment selection, and monitoring in appropriate oncology settings.
Further development of laboratory infrastructure, access to validated tests, and greater clinical awareness are likely to influence adoption.
Qatar and Oman
Qatar and Oman represent additional opportunities as regional healthcare systems expand access to advanced diagnostics and precision medicine. The pace of growth will depend on investments in molecular testing infrastructure, specialist expertise, clinical integration, and the availability of appropriate reimbursement arrangements.
GCC Liquid Biopsy Market Segmentation
The GCC liquid biopsy market can be analyzed across the following segments:
| Segment | Categories |
|---|---|
| Product | Kits and reagents; platforms and instruments; services |
| Application | Cancer therapeutic applications; reproductive health; other therapeutic applications |
| Circulating biomarkers | Circulating tumor cells; circulating tumor DNA; cell-free DNA; extracellular vesicles; other biomarkers |
| End user | Hospitals; diagnostic laboratories; point-of-care testing; academic institutes; others |
| Geography | Saudi Arabia; UAE; Kuwait; Qatar; Oman; Bahrain; rest of GCC |
These segments help market participants identify opportunities across diagnostic consumables, molecular testing infrastructure, clinical applications, and end-user organizations.
Competitive Landscape and Key Companies
The GCC liquid biopsy market includes international diagnostic technology providers, molecular testing companies, sequencing specialists, and laboratory solution manufacturers.
Key companies covered in the market analysis include:
- F. Hoffmann-La Roche Ltd.
- Bio-Rad Laboratories
- Thermo Fisher Scientific Inc.
- Johnson & Johnson
- Guardant Health Inc.
- QIAGEN N.V.
- Sysmex
Competition is influenced by test sensitivity, analytical capabilities, genomic coverage, turnaround time, clinical validation, laboratory integration, and the ability to support clinicians with actionable results.
Product developments worldwide also illustrate the direction of the industry. In 2025, Labcorp announced the clinical availability of Plasma Complete, a ctDNA-based comprehensive genomic profiling test for patients with advanced solid tumors. NeoGenomics also introduced NEO PanTracer LBx, a blood-based genomic profiling test designed to support therapy selection, clinical-trial matching, and longitudinal disease monitoring.
Although these developments are not specific to GCC launches, they demonstrate the broader technological progress shaping the market.
Renub Research’s competitive analysis covers company overviews, key personnel, recent developments, SWOT analysis, and revenue analysis.
Future Outlook: GCC Liquid Biopsy Market Through 2034
The GCC liquid biopsy market is projected to grow from US$ 11.61 million in 2025 to US$ 36.58 million by 2034, at a CAGR of 13.6% during 2026–2034.
Future growth is expected to be supported by rising cancer incidence, increasing adoption of precision oncology, improvements in molecular testing, and investments in advanced healthcare infrastructure.
Saudi Arabia and the UAE are positioned to remain important markets because of their developing genomic-medicine capabilities and clinical partnerships. Other GCC countries may also benefit from greater access to advanced laboratory services and regional collaboration.
Nevertheless, market expansion will depend on addressing testing costs, reimbursement limitations, workforce requirements, and the need for consistent clinical validation. Wider adoption will also require clear guidance on when liquid biopsy should complement or be used alongside conventional diagnostic procedures.
Overall, liquid biopsy represents a promising area of growth within the GCC’s advanced diagnostics industry. Continued technological development and investment in clinical capabilities are expected to create opportunities for diagnostic manufacturers, laboratory providers, healthcare institutions, and precision-medicine companies through 2034.
Frequently Asked Questions (FAQs)
1. What is the GCC liquid biopsy market size?
The GCC liquid biopsy market is projected to reach US$ 36.58 million by 2034, increasing from US$ 11.61 million in 2025, according to Renub Research.
2. What is the CAGR of the GCC liquid biopsy market?
The market is expected to register a compound annual growth rate (CAGR) of 13.6% during the forecast period from 2026 to 2034.
3. What are the major factors driving market growth?
Key drivers include rising cancer incidence, growing demand for precision oncology, investments in genomic medicine, healthcare modernization, and increasing adoption of NGS-based molecular diagnostics.
4. Which countries are included in the GCC liquid biopsy market?
The market covers Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, and the rest of the GCC.
5. What are the main applications of liquid biopsy?
Applications include tumor genomic profiling, treatment selection, monitoring treatment response, identifying emerging resistance mutations, assessing minimal residual disease, and evaluating recurrence risk in appropriate clinical settings. Cell-free DNA testing also supports non-invasive prenatal screening.
6. What are the key challenges in the GCC liquid biopsy market?
High testing costs, limited reimbursement, technical complexity, the need for specialized laboratory infrastructure, and shortages of trained molecular-diagnostics professionals are important challenges.
7. Who are the major companies in the GCC liquid biopsy market?
Key companies covered include Roche, Bio-Rad Laboratories, Thermo Fisher Scientific, Johnson & Johnson, Guardant Health, QIAGEN, and Sysmex.
8. What opportunities will shape the GCC liquid biopsy market through 2034?
Important opportunities include wider adoption of ctDNA testing, expansion of NGS-based genomic profiling, growing demand for diagnostic kits and reagents, increased laboratory capacity, and integration of precision medicine into cancer care.
About Renub Research
Renub Research provides market intelligence and industry analysis to help businesses understand market size, growth drivers, competitive dynamics, emerging opportunities, and future industry trends. Its GCC liquid biopsy market research examines product categories, clinical applications, circulating biomarkers, end users, country-level developments, and key companies through 2034.
Explore the full report: GCC Liquid Biopsy Market
